PMN 400
Alternative Names: Alpha-synuclein vaccine - ProMIS Neurosciences; PMN-400Latest Information Update: 01 Mar 2024
At a glance
- Originator ProMIS Neurosciences
- Class Conjugate vaccines; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Neurodegenerative disorders